Nano 595 Room,Life Sciences Institute, Zhejiang University
Primary liver cancer is the second most deadly cancer in men and fifth most prevalent cancer worldwide. Tumor heterogeneity causes the significant difficulty in liver cancer diagnosis and treatment, leading to poor outcome for cancer patients. My lab focuses on investigating personalized medicine via studying tumor heterogeneity in liver cancer. Hepatocellular carcinoma (HCC) is the major type of liver cancer, and presents significant heterogeneity. Through deciphering HCC tumor heterogeneity at the molecular level, we might be able to sub-classify tumors, and identify key drivers and critical target genes in each subgroup, with the hope of largely increasing the survival for HCC patients via precision therapeutic methods.